{"id":59286,"date":"2026-03-11T16:31:59","date_gmt":"2026-03-11T08:31:59","guid":{"rendered":"https:\/\/flcube.com\/?p=59286"},"modified":"2026-03-11T16:31:59","modified_gmt":"2026-03-11T08:31:59","slug":"jjs-akeega-wins-eu-approval-for-mhspc-parp-abiraterone-combo-expands-to-earlier-line-prostate-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59286","title":{"rendered":"J&amp;J&#8217;s AKEEGA Wins EU Approval for mHSPC \u2013 PARP\/Abiraterone Combo Expands to Earlier-Line Prostate Cancer"},"content":{"rendered":"\n<p><strong>Johnson &amp; Johnson<\/strong> (J&amp;J, <a href=\"https:\/\/www.google.com\/finance\/quote\/JNJ:NYSE\">NYSE: JNJ<\/a>) announced that the <strong>European Commission (EC)<\/strong> has approved a <strong>new indication<\/strong> for <strong>AKEEGA (niraparib and abiraterone acetate dual-action tablet)<\/strong> for <strong>metastatic hormone-sensitive prostate cancer (mHSPC)<\/strong> patients with <strong>BRCA1\/2 mutations<\/strong> (germline and\/or somatic), to be used in combination with <strong>prednisone\/prednisolone (AAP)<\/strong> and <strong>androgen deprivation therapy (ADT)<\/strong>. The approval <strong>expands AKEEGA from its April 2023 mCRPC indication<\/strong> to <strong>first-line mHSPC<\/strong>, capturing the <strong>largest addressable prostate cancer population<\/strong> with a <strong>dual-mechanism targeted therapy<\/strong> addressing both <strong>androgen receptor axis<\/strong> and <strong>BRCA1\/2-driven tumor vulnerabilities<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Authority<\/strong><\/td><td>European Commission (EC)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>New indication (line extension)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>AKEEGA (niraparib + abiraterone acetate dual-action tablet)<\/td><\/tr><tr><td><strong>New Indication<\/strong><\/td><td>mHSPC with BRCA1\/2 mutations (germline and\/or somatic)<\/td><\/tr><tr><td><strong>Combination<\/strong><\/td><td>+ prednisone\/prednisolone (AAP) + androgen deprivation therapy (ADT)<\/td><\/tr><tr><td><strong>Prior EU Approval<\/strong><\/td><td>April 2023 \u2013 BRCA1\/2-mutated mCRPC<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>PARP inhibition (niraparib) + androgen biosynthesis inhibition (abiraterone)<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>9\u202fMar\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-dual-mechanism-rationale\">Drug Profile &amp; Dual-Mechanism Rationale<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Mechanism<\/th><th>Contribution<\/th><\/tr><\/thead><tbody><tr><td><strong>Niraparib<\/strong><\/td><td>Highly selective PARP inhibitor<\/td><td>Synthetic lethality in BRCA1\/2-mutant tumors; blocks DNA repair<\/td><\/tr><tr><td><strong>Abiraterone Acetate<\/strong><\/td><td>CYP17 inhibitor (androgen biosynthesis)<\/td><td>Suppresses androgen receptor axis signaling<\/td><\/tr><tr><td><strong>Prednisone\/Prednisolone<\/strong><\/td><td>Glucocorticoid<\/td><td>Manages abiraterone-induced mineralocorticoid excess<\/td><\/tr><tr><td><strong>ADT<\/strong><\/td><td>LHRH agonist\/antagonist<\/td><td>Castration-level testosterone suppression<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Synergy in BRCA1\/2-mutant mHSPC:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Androgen deprivation:<\/strong> Foundation of mHSPC treatment<\/li>\n\n\n\n<li><strong>PARP inhibition:<\/strong> Exploits DNA repair deficiency in BRCA-mutant clones emerging under ADT pressure<\/li>\n\n\n\n<li><strong>Early Intervention:<\/strong> Prevents castration resistance development; prolongs hormone-sensitive period<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-amp-commercial-impact\">Clinical &amp; Commercial Impact<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Strategic Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>Line of Therapy Expansion<\/strong><\/td><td>Moves from mCRPC (end-stage) to mHSPC (first-line) \u2013 <strong>5-10x patient population increase<\/strong><\/td><\/tr><tr><td><strong>BRCA Testing<\/strong><\/td><td>Drives germline\/somatic testing in newly diagnosed mHSPC; companion diagnostic revenue synergy<\/td><\/tr><tr><td><strong>Competitive Positioning<\/strong><\/td><td>Challenges standard ADT + docetaxel\/abiraterone with targeted combination; potential for OS benefit<\/td><\/tr><tr><td><strong>Revenue Forecast<\/strong><\/td><td>Analysts project <strong>\u20ac500M-1B incremental annual EU sales<\/strong> with mHSPC expansion; total AKEEGA franchise approaching <strong>$2B global peak<\/strong><\/td><\/tr><tr><td><strong>U.S. Implications<\/strong><\/td><td>FDA sNDA filing anticipated; PROpel trial data supports earlier-line U.S. approval<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Competitor<\/th><th>Product<\/th><th>Mechanism<\/th><th>mHSPC Status<\/th><th>AKEEGA Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>Janssen (J&amp;J)<\/strong><\/td><td>Zytiga (abiraterone) + ADT<\/td><td>Androgen inhibition<\/td><td>Standard of care<\/td><td>Adds PARP for BRCA-mutant subset; potential superiority<\/td><\/tr><tr><td><strong>Pfizer\/Astellas<\/strong><\/td><td>Xtandi (enzalutamide) + ADT<\/td><td>Androgen receptor blockade<\/td><td>Standard of care<\/td><td>Mechanistic differentiation; biomarker-driven selection<\/td><\/tr><tr><td><strong>AstraZeneca<\/strong><\/td><td>Lynparza (olaparib) + abiraterone<\/td><td>PARP + androgen inhibition<\/td><td>PROpel trial (approved mCRPC)<\/td><td>First dual-action tablet; convenience advantage<\/td><\/tr><tr><td><strong>J&amp;J<\/strong><\/td><td><strong>AKEEGA<\/strong><\/td><td><strong>PARP + abiraterone fixed-dose combination<\/strong><\/td><td><strong>Approved (mHSPC BRCA+)<\/strong><\/td><td><strong>Single tablet; first-line BRCA-targeted therapy<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-timeline-amp-launch-execution\">Regulatory Timeline &amp; Launch Execution<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Milestone<\/th><th>Timeline<\/th><th>Status<\/th><\/tr><\/thead><tbody><tr><td><strong>EC Approval<\/strong><\/td><td>March 2026<\/td><td>Granted (mHSPC BRCA+)<\/td><\/tr><tr><td><strong>EU Member State Implementation<\/strong><\/td><td>Q2-Q3 2026<\/td><td>National pricing and reimbursement negotiations<\/td><\/tr><tr><td><strong>Commercial Launch<\/strong><\/td><td>Q3 2026 (EU)<\/td><td>Hospital oncology\/urology department access<\/td><\/tr><tr><td><strong>U.S. sNDA<\/strong><\/td><td>2026<\/td><td>FDA submission anticipated based on PROpel mHSPC data<\/td><\/tr><tr><td><strong>Global Expansion<\/strong><\/td><td>2026-2027<\/td><td>Japan, China regulatory filings<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding commercial launch performance, U.S. regulatory expansion, and competitive positioning for AKEEGA in mHSPC. Actual results may differ due to reimbursement negotiations, BRCA testing adoption rates, and competitive dynamics with PARP inhibitor combinations.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Johnson &amp; Johnson (J&amp;J, NYSE: JNJ) announced that the European Commission (EC) has approved a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":59288,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,150,149,858,15],"class_list":["post-59286","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-jj","tag-johnson-johnson","tag-nyse-jnj","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>J&amp;J&#039;s AKEEGA Wins EU Approval for mHSPC \u2013 PARP\/Abiraterone Combo Expands to Earlier-Line Prostate Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Johnson &amp; Johnson (J&amp;J, NYSE: JNJ) announced that the European Commission (EC) has approved a new indication for AKEEGA (niraparib and abiraterone acetate dual-action tablet) for metastatic hormone-sensitive prostate cancer (mHSPC) patients with BRCA1\/2 mutations (germline and\/or somatic), to be used in combination with prednisone\/prednisolone (AAP) and androgen deprivation therapy (ADT). The approval expands AKEEGA from its April 2023 mCRPC indication to first-line mHSPC, capturing the largest addressable prostate cancer population with a dual-mechanism targeted therapy addressing both androgen receptor axis and BRCA1\/2-driven tumor vulnerabilities.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59286\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"J&amp;J&#039;s AKEEGA Wins EU Approval for mHSPC \u2013 PARP\/Abiraterone Combo Expands to Earlier-Line Prostate Cancer\" \/>\n<meta property=\"og:description\" content=\"Johnson &amp; Johnson (J&amp;J, NYSE: JNJ) announced that the European Commission (EC) has approved a new indication for AKEEGA (niraparib and abiraterone acetate dual-action tablet) for metastatic hormone-sensitive prostate cancer (mHSPC) patients with BRCA1\/2 mutations (germline and\/or somatic), to be used in combination with prednisone\/prednisolone (AAP) and androgen deprivation therapy (ADT). The approval expands AKEEGA from its April 2023 mCRPC indication to first-line mHSPC, capturing the largest addressable prostate cancer population with a dual-mechanism targeted therapy addressing both androgen receptor axis and BRCA1\/2-driven tumor vulnerabilities.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59286\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-11T08:31:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1106.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59286#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59286\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"J&amp;J&#8217;s AKEEGA Wins EU Approval for mHSPC \u2013 PARP\\\/Abiraterone Combo Expands to Earlier-Line Prostate Cancer\",\"datePublished\":\"2026-03-11T08:31:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59286\"},\"wordCount\":504,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59286#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1106.webp\",\"keywords\":[\"Cancer\",\"J&amp;J\",\"Johnson &amp; Johnson\",\"NYSE: JNJ\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59286#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59286\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59286\",\"name\":\"J&amp;J's AKEEGA Wins EU Approval for mHSPC \u2013 PARP\\\/Abiraterone Combo Expands to Earlier-Line Prostate Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59286#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59286#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1106.webp\",\"datePublished\":\"2026-03-11T08:31:59+00:00\",\"description\":\"Johnson & Johnson (J&J, NYSE: JNJ) announced that the European Commission (EC) has approved a new indication for AKEEGA (niraparib and abiraterone acetate dual-action tablet) for metastatic hormone-sensitive prostate cancer (mHSPC) patients with BRCA1\\\/2 mutations (germline and\\\/or somatic), to be used in combination with prednisone\\\/prednisolone (AAP) and androgen deprivation therapy (ADT). The approval expands AKEEGA from its April 2023 mCRPC indication to first-line mHSPC, capturing the largest addressable prostate cancer population with a dual-mechanism targeted therapy addressing both androgen receptor axis and BRCA1\\\/2-driven tumor vulnerabilities.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59286#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59286\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59286#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1106.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1106.webp\",\"width\":1080,\"height\":608,\"caption\":\"J&J's AKEEGA Wins EU Approval for mHSPC \u2013 PARP\\\/Abiraterone Combo Expands to Earlier-Line Prostate Cancer\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59286#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"J&amp;J&#8217;s AKEEGA Wins EU Approval for mHSPC \u2013 PARP\\\/Abiraterone Combo Expands to Earlier-Line Prostate Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"J&amp;J's AKEEGA Wins EU Approval for mHSPC \u2013 PARP\/Abiraterone Combo Expands to Earlier-Line Prostate Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"Johnson & Johnson (J&J, NYSE: JNJ) announced that the European Commission (EC) has approved a new indication for AKEEGA (niraparib and abiraterone acetate dual-action tablet) for metastatic hormone-sensitive prostate cancer (mHSPC) patients with BRCA1\/2 mutations (germline and\/or somatic), to be used in combination with prednisone\/prednisolone (AAP) and androgen deprivation therapy (ADT). The approval expands AKEEGA from its April 2023 mCRPC indication to first-line mHSPC, capturing the largest addressable prostate cancer population with a dual-mechanism targeted therapy addressing both androgen receptor axis and BRCA1\/2-driven tumor vulnerabilities.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59286","og_locale":"en_US","og_type":"article","og_title":"J&amp;J's AKEEGA Wins EU Approval for mHSPC \u2013 PARP\/Abiraterone Combo Expands to Earlier-Line Prostate Cancer","og_description":"Johnson & Johnson (J&J, NYSE: JNJ) announced that the European Commission (EC) has approved a new indication for AKEEGA (niraparib and abiraterone acetate dual-action tablet) for metastatic hormone-sensitive prostate cancer (mHSPC) patients with BRCA1\/2 mutations (germline and\/or somatic), to be used in combination with prednisone\/prednisolone (AAP) and androgen deprivation therapy (ADT). The approval expands AKEEGA from its April 2023 mCRPC indication to first-line mHSPC, capturing the largest addressable prostate cancer population with a dual-mechanism targeted therapy addressing both androgen receptor axis and BRCA1\/2-driven tumor vulnerabilities.","og_url":"https:\/\/flcube.com\/?p=59286","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-11T08:31:59+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1106.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59286#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59286"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"J&amp;J&#8217;s AKEEGA Wins EU Approval for mHSPC \u2013 PARP\/Abiraterone Combo Expands to Earlier-Line Prostate Cancer","datePublished":"2026-03-11T08:31:59+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59286"},"wordCount":504,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=59286#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1106.webp","keywords":["Cancer","J&amp;J","Johnson &amp; Johnson","NYSE: JNJ","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59286#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59286","url":"https:\/\/flcube.com\/?p=59286","name":"J&amp;J's AKEEGA Wins EU Approval for mHSPC \u2013 PARP\/Abiraterone Combo Expands to Earlier-Line Prostate Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=59286#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=59286#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1106.webp","datePublished":"2026-03-11T08:31:59+00:00","description":"Johnson & Johnson (J&J, NYSE: JNJ) announced that the European Commission (EC) has approved a new indication for AKEEGA (niraparib and abiraterone acetate dual-action tablet) for metastatic hormone-sensitive prostate cancer (mHSPC) patients with BRCA1\/2 mutations (germline and\/or somatic), to be used in combination with prednisone\/prednisolone (AAP) and androgen deprivation therapy (ADT). The approval expands AKEEGA from its April 2023 mCRPC indication to first-line mHSPC, capturing the largest addressable prostate cancer population with a dual-mechanism targeted therapy addressing both androgen receptor axis and BRCA1\/2-driven tumor vulnerabilities.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59286#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59286"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=59286#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1106.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1106.webp","width":1080,"height":608,"caption":"J&J's AKEEGA Wins EU Approval for mHSPC \u2013 PARP\/Abiraterone Combo Expands to Earlier-Line Prostate Cancer"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59286#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"J&amp;J&#8217;s AKEEGA Wins EU Approval for mHSPC \u2013 PARP\/Abiraterone Combo Expands to Earlier-Line Prostate Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1106.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59286","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59286"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59286\/revisions"}],"predecessor-version":[{"id":59289,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59286\/revisions\/59289"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/59288"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59286"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59286"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59286"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}